Tryptamine Therapeutics Limited
TYPTF
$0.02
$0.007.14%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 11/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 506.60K | 496.10K | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 506.60K | 496.10K | -- | -- | -- |
| Cost of Revenue | 197.80K | 193.70K | 580.30K | 596.70K | -- |
| Gross Profit | 308.80K | 302.40K | -580.30K | -596.70K | -- |
| SG&A Expenses | 675.80K | 661.80K | 706.00K | 726.00K | 505.90K |
| Depreciation & Amortization | 10.90K | 10.70K | 6.60K | 6.80K | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 884.50K | 866.20K | 1.29M | 1.33M | 696.50K |
| Operating Income | -377.90K | -370.10K | -1.29M | -1.33M | -696.50K |
| Income Before Tax | -418.40K | -409.70K | -1.31M | -1.35M | -850.10K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -418.40K | -409.70K | -1.31M | -1.35M | -850.10K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -418.40K | -409.70K | -1.31M | -1.35M | -850.10K |
| EBIT | -377.90K | -370.10K | -1.29M | -1.33M | -696.50K |
| EBITDA | -367.00K | -359.40K | -1.29M | -1.32M | -- |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| Average Basic Shares Outstanding | 1.61B | 1.61B | 1.14B | 1.14B | 93.38M |
| Average Diluted Shares Outstanding | 1.61B | 1.61B | 1.14B | 1.14B | 93.38M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |